|
1
|
Estey EH: Acute myeloid leukemia: 2013
update on risk-stratification and management. Am J Hematol.
88:318–327. 2013.PubMed/NCBI
|
|
2
|
Davis AS, Viera AJ and Mead MD: Leukemia:
An overview for primary care. Am Fam Physician. 89:731–738.
2014.PubMed/NCBI
|
|
3
|
Liu L, Zhang Y, Jin Z, Zhang X, Zhao G, Si
Y, Lin G, Ma A, Sun Y, Wang L and Wu D: Increasing the dose of
aclarubicin in low-dose cytarabine and aclarubicin in combination
with granulocyte colony-stimulating factor (CAG regimen) can safely
and effectively treat relapsed or refractory acute myeloid
leukemia. Int J Hematol. 99:603–608. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Carlotti ME, Carpignano R, Gasco MR and
Trotta M: Optimization of emulsions. Int J Cosmet Sci. 13:209–219.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang J, Lü S, Yang J, Song X, Chen L,
Huang C, Hou J and Zhang W: A homoharringtonine-based induction
regimen for the treatment of elderly patients with acute myeloid
leukemia: A single center experience from China. J Hematol Oncol.
2:322009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jin J, Jiang DZ, Mai WY, Meng HT, Qian WB,
Tong HY, Huang J, Mao LP, Tong Y, Wang L, et al: Homoharringtonine
in combination with cytarabine and aclarubicin resulted in high
complete remission rate after the first induction therapy in
patients with de novo acute myeloid leukemia. Leukemia.
20:1361–1367. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee YJ, Moon JH, Kim JG, Chae YS, Kang BW,
Lee SJ, Choi JY, Shin HC, Seo JW and Sohn SK: Prospective
randomization trial of G-CSF-primed induction regimen versus
standard regimen in patients with AML. Chonnam Med J. 47:80–84.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huang H, Qin Y, Xu R, You X, Teng R, Yang
L, Xu M and Liu H: Combination therapy with arsenic trioxide,
all-trans retinoic acid and chemotherapy in acute promyelocytic
leukemia patients with various relapse risks. Leuk Res. 36:841–845.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lo-Coco F and Hasan SK: Understanding the
molecular pathogenesis of acute promyelocytic leukemia. Best Pract
Res Clin Haematol. 27:3–9. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stirewalt DL, Pogosova-Agadjanyan EL,
Tsuchiya K, Joaquin J and Meshinchi S: Copy-neutral loss of
heterozygosity is prevalent and a late event in the pathogenesis of
FLT3/ITD AML. Blood Cancer J. 4:e2082014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tao YF, Xu LX, Lu J, Cao L, Li ZH, Hu SY,
Wang NN, Du XJ, Sun LC, Zhao WL, et al: Metallothionein III (MT3)
is a putative tumor suppressor gene that is frequently inactivated
in pediatric acute myeloid leukemia by promoter hypermethylation. J
Transl Med. 12:1822014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Conway O'Brien E, Prideaux S and Chevassut
T: The epigenetic landscape of acute myeloid leukemia. Adv Hematol.
2014:1031752014.PubMed/NCBI
|
|
13
|
Jiang D, Hong Q, Shen Y, Xu Y, Zhu H, Li
Y, Xu C, Ouyang G and Duan S: The diagnostic value of DNA
methylation in leukemia: A systematic review and meta-analysis.
PLoS One. 9:e968222014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sonnet M, Claus R, Becker N, Zucknick M,
Petersen J, Lipka DB, Oakes CC, Andrulis M, Lier A, Milsom MD, et
al: Early aberrant DNA methylation events in a mouse model of acute
myeloid leukemia. Genome Med. 6:342014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pluta A, Nyman U, Joseph B, Robak T,
Zhivotovsky B and Smolewski P: The role of p73 in hematological
malignancies. Leukemia. 20:757–766. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Esteller M: Profiling aberrant DNA
methylation in hematologic neoplasms: A view from the tip of the
iceberg. Clin Immunol. 109:80–88. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cancer Genome Atlas Research Network:
Genomic and epigenomic landscapes of adult de novo acute myeloid
leukemia. N Engl J Med. 368:2059–2074. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tao YF, Ni J, Lu J, Wang N, Xiao PF, Zhao
WL, Wu D, Pang L, Wang J, Feng X and Pan J: The promoter of miR-663
is hypermethylated in Chinese pediatric acute myeloid leukemia
(AML). BMC Med Genet. 14:742013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Baylin SB and Jones PA: A decade of
exploring the cancer epigenome-biological and translational
implications. Nat Rev Cancer. 11:726–734. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Leone G, Voso MT, Teofili L and Lübbert M:
Inhibitors of DNA methylation in the treatment of hematological
malignancies and MDS. Clin Immunol. 109:89–102. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu X, Lam EK, Wang X, Zhang J, Cheng YY,
Lam YW, Ng EK, Yu J, Chan FK, Jin H and Sung JJ: Promoter
hypermethylation mediates downregulation of thiamine receptor
SLC19A3 in gastric cancer. Tumour Biol. 30:242–248. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kwong J, Lee JY, Wong KK, Zhou X, Wong DT,
Lo KW, Welch WR, Berkowitz RS and Mok SC: Candidate
tumor-suppressor gene DLEC1 is frequently downregulated by promoter
hypermethylation and histone hypoacetylation in human epithelial
ovarian cancer. Neoplasia. 8:268–278. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Walter RB, Othus M, Burnett AK, Löwenberg
B, Kantarjian HM, Ossenkoppele GJ, Hills RK, van Montfort KG,
Ravandi F, et al: Significance of FAB subclassification of ‘acute
myeloid leukemia, NOS’ in the 2008 WHO classification: Analysis of
5848 newly diagnosed patients. Blood. 121:2424–2431. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fasan A, Alpermann T, Haferlach C,
Grossmann V, Roller A, Kohlmann A, Eder C, Kern W, Haferlach T and
Schnittger S: Frequency and prognostic impact of CEBPA proximal,
distal and core promoter methylation in normal karyotype AML: A
study on 623 cases. PLoS One. 8:e543652013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Marzese DM, Huang SK and Hoon DS: In situ
sodium bisulfite modification of genomic DNA from microdissected
melanoma paraffin-embedded archival tissues. Methods Mol Biol. Dec
13–2015.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen C, Wang L, Liao Q, Huang Y, Ye H,
Chen F, Xu L, Ye M and Duan S: Hypermethylation of EDNRB promoter
contributes to the risk of colorectal cancer. Diagn Pathol.
8:1992013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vidal DO, Paixão VA, Brait M, Souto EX,
Caballero OL, Lopes LF and Vettore AL: Aberrant methylation in
pediatric myelodysplastic syndrome. Leuk Res. 31:175–181. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang L, Shi J, Xu L, Shi B, Hou P and Ji
M: Aberrant DNA methylation of drug metabolism and transport genes
in nodular goiter. Thyroid Res. 4:152011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Qu X, Jiang N, Xu F, Shao L, Tang G,
Wilkinson B and Liu W: Cloning, sequencing and characterization of
the biosynthetic gene cluster of sanglifehrin A, a potent
cyclophilin inhibitor. Molecular Biosyst. 7:852–861. 2011.
View Article : Google Scholar
|
|
30
|
Moreira MA, Bagni C, de Pinho MB,
Mac-Cormick TM, dos Santos Mota M, Pinto-Silva FE, Daflon-Yunes N
and Rumjanek VM: Changes in gene expression profile in two
multidrug resistant cell lines derived from a same drug sensitive
cell line. Leuk Res. 38:983–987. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Si XX and Sun YJ: Aberrant DNA methylation
and drug resistance of tumor cells. Yi Chuan. 36:411–419. 2014.(In
Chinese). PubMed/NCBI
|
|
32
|
Li J, Bi L, Lin Y, Lu Z and Hou G:
Clinicopathological significance and potential drug target of
p15INK4B in multiple myeloma. Drug Des Devel Ther. 8:2129–2136.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Santos FP, Kantarjian H, Garcia-Manero G,
Issa JP and Ravandi F: Decitabine in the treatment of
myelodysplastic syndromes. Expert Rev Anticancer Ther. 10:9–22.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Song LX, Xu L and Li X, Chang CK, Zhang Y,
Wu LY, He Q, Zhang QX and Li X: Clinical outcome of treatment with
a combined regimen of decitabine and aclacinomycin/cytarabine for
patients with refractory acute myeloid leukemia. Ann Hematol.
91:1879–1886. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Subramanian VS, Marchant JS and Said HM:
Biotin-responsive basal ganglia disease-linked mutations inhibit
thiamine transport via hTHTR2: Biotin is not a substrate for
hTHTR2. Am J Physiol Cell Physiol. 291:C851–C859. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ikehata M, Ueda K and Iwakawa S: Different
involvement of DNA methylation and histone deacetylation in the
expression of solute-carrier transporters in 4 colon cancer cell
lines. Biol Pharm Bull. 35:301–307. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang Z, Li L, Su X, Gao Z, Srivastava G,
Murray PG, Ambinder R and Tao Q: Epigenetic silencing of the 3p22
tumor suppressor DLEC1 by promoter CpG methylation in non-Hodgkin
and Hodgkin lymphomas. J Transl Med. 10:2092012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Seng TJ, Currey N, Cooper WA, Lee CS, Chan
C, Horvath L, Sutherland RL, Kennedy C, McCaughan B and
Kohonen-Corish MR: DLEC1 and MLH1 promoter methylation are
associated with poor prognosis in non-small cell lung carcinoma. Br
J Cancer. 2:375–82. 2008. View Article : Google Scholar
|
